Stuart Sealfon is currently a Professor in the Departments of Neuorology, Neuroscience,
and Pharmacological Sciences at the Icahn School of Medicine at Mt. Sinai. He is a physician–systems biologist pursuing a translational research program based on identifying emergent systems level responses from molecular changes. He directs
the multi-institution Program for Research on Immune Modeling and Experimentation (PRiME), continuously funded by NIH from 2005-2020, a gonadotrope signaling research program (continuously funded by NIH for 30 years), an NIH Physical Activity common
fund Genomics, Epigenomics and Transcriptomics site, a DARPA-funded consortium to identify epigenetic signatures of disease and other exposures in blood, and the inter-departmental Center for Advanced Research on Diagnostic Assays at Mount Sinai.
His translational research has led to the identification of brain and pituitary drug targets and has contributed to the discovery of a new neuroendocrine drug, Elagolix, for which FDA has approved. Active research areas include (1) developing and
implementing computational algorithms for biomarker discovery, (2) big data mining and gene network prediction, (3) identifying blood RNA expression signatures to improve the diagnosis and individualized therapy of brain diseases, (4) identifying
the mechanism of frequency-dependent signal decoding in the pituitary gonadotrope that underlies reproductive function and dysfunction, and (5) developing experimental based mathematical models of the early emergent response to influenza virus infection.
His research involves data intensive, high-throughput experimentation to generate high dimensional datasets of molecular responses and relationships and single cell studies in conjunction with top-down computational analysis and algorithm development
and bottom-up stochastic and deterministic mathematical modeling to interpret these datasets.
Email: stuart.sealfon@mssm.edu
Phone: (212) 241-7327
Link: https://icahn.mssm.edu/profiles/stuart-c-sealfon